Neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein-antibody associated disease incur significant costs for individuals, their families and for society, according to study results published in Neurology.
“Until summer 2019, [neuromyelitis optica spectrum disorder (NMOSD)] was globally treated off-label with standard immunotherapeutics, preferably rituximab, azathioprine or mycophenolate mofetil,” Martin W. Hümmert, MD, of the department of neurology at Hannover Medical School in Germany, and colleagues wrote. “New treatments have been and are